PURPOSE: To compare the clinical and polysomnographic variables in patients who underwent PSG and the differences related to gender.
METHODS: Prospective analysis of adult patients referred to a Brazilian sleep center for PSG from January 2006 to April 2010. All patients have OSA diagnosis based on PSG: apnea/hypopnea index [AHI] ≥ 5 events/hr). The variables evaluated were: gender, age, body-mass index (BMI), neck circumference (NC), Epworth Sleepiness Scale (ESS), AHI, and the lowest oxygen saturation (LSO2).The continuous variables were summarized by medians. Statistical analyses were obtained by Mann-Whitney test and ANOVA. The differences of the OSA frequency were expressed as odds ratio (OR) and 95% confidence intervals (95% CI). The correlation between the variables was evaluated using a Spearman rank correlation coefficient (rs).
RESULTS: 13,950 patients (61.3% males) were studied. Of these, the men were, in relation to women, younger (44.0 vs. 49.0 yrs), with higher BMI (28.0 vs. 27.0 Kg/m2), higher NC (41.0 vs. 36.0 cm), higher ESS (10.0 vs. 9.0 points), higher AHI (19.9 vs. 7.7/hr), and lower LSO2 (85.0 vs. 88.0%); all of them with p< 0.001. The frequency of moderate/severe OSA (AHI ≥ 15 events/hr) was different between men and women: 59.5% vs. 32.4%, p< 0.001. The chance of having moderate/severe OSA in men (vs. women) was OR=3.06 (95% CI=2.85-3.30). In men and in women, the age ≥ 45 years was associated with increase in the OSA frequency: 69.7% vs. 44.4%, respectively. This age influence was more visible in women than men: OR=4.43 (95% CI=3.87-5.08) vs. OR=2.35 (95% CI=2.15-2.56). The correlation between age and AHI was better in women than men (respectively, rs=0.47 vs. rs=0.25; p< 0.001).
CONCLUSION: The moderate/severe OSA was higher in men than women. In both, this frequency was higher in patients with age ≥ 45 years, but the influence of the age was higher in women, possibly due to the menopausal status.
CLINICAL IMPLICATIONS: In women, OSA diagnosis needs a strong suspicion mainly above 45 yrs.
DISCLOSURE: Flavio da Silveira, No Financial Disclosure Information; No Product/Research Disclosure Information